Pfizer's Cancer Drug Patent Withstands Mylan Challenge
A Delaware federal judge ruled Wednesday that Pfizer Inc.'s patent for cancer drug Sutent was nonobvious and could stand, despite a challenge from Mylan Pharmaceuticals Inc. in Pfizer's suit seeking to...To view the full article, register now.
Already a subscriber? Click here to view full article